

Research Article**Differential effect of morphine on spatial learning and memory in rat model of streptozotocin-induced dementia of Alzheimer's type****Sedighe-Sadat Hosseini¹, Nazanin Samandari²,
Asra Ghiyasi² and Mohammad Hossein Esmaeili*²**¹Telemedicine Infertility Treatment Center, ACECR branch of Qazvin, Qazvin, Iran²Cellular and Molecular Research Center & Department of Physiology,
Qazvin University of Medical Sciences, Qazvin, Iran

*Corresponding Author: esmail66@yahoo.com

ABSTRACT

Introduction: Alzheimer's disease (AD) is characterized by the accumulation of intra and extracellular amyloid- β (A β) plaques, and hyperphosphorylated Tau protein and synaptic/neuronal loss. Certain experimental models support morphine can play a beneficial role against damage in the neuronal system. It has been shown that morphine application immediately after hypoxia decreases infarction volume in the rat brain of hypoxia-ischemia model. The aim of present study, was to investigate the therapeutic efficacy of morphine on learning and memory in streptozotocin (STZ) Rat Model of AD.

Methods: 60 male Wistar rats were divided to: control, vehicle and groups treated with STZ and STZ plus saline or morphine. For induction of AD, STZ (3 mg/kg, 10 μ l/injection site) were administered bilaterally into lateral ventricles. Morphine (1, 2.5 and 5 mg/kg, i.p.) or saline (0.2ml), were injected daily, one week after operation for 10 days before training. All rats were trained in the Morris water maze (MWM) 3 weeks after stereotaxic operation. On the training days, rats were given a daily session of 4 trials per day for 6 consecutive days, 24 h after the last acquisition session, a 'probe trial' was used to assess the spatial memory.

Results: The results indicated that i.c.v. injection of STZ significantly increased escape latency and Swimming distance to find the hidden platform in comparison with the control and saline groups ($P < 0.05$). The amnesic effect of STZ was prevented in rats treated with Low doses of Morphine (1 and 2.5 mg/kg/day) whereas treatment with high doses of Morphine (5 mg/kg) led to further impairment of learning and memory in the STZ rat model of sporadic AD. So The latency time and Swimming distance to find the platform in the Morphine (2.5 mg/kg) group rats were significantly lower than those in the other STZ-induced AD groups ($P < 0.05$) conversely, the percentage of time spent and distance swimming in the target quadrant in the STZ+Morphine (2.5 mg/kg) group rats were significantly higher than those in the other STZ-induced AD groups ($P < 0.001$).

Conclusion: Our data show that Low doses of Morphine (1 and 2.5 mg/kg), facilitates, whereas higher doses of Morphine (5 mg/kg), impairs, learning and memory in STZ-induced rat model of sporadic AD. The results suggest that chronic treatment with Low doses of Morphine can play a beneficial role against damage in the neuronal system, which in turn reversed the impairment of spatial memory acquisition induced by i.c.v. injection of STZ.

INTRODUCTION

AD is characterized by the accumulation of intra and extracellular amyloid- β (A β) plaques, and hyperphosphorylated Tau protein and synaptic/neuronal loss (Price and Sisodia, 1998, Li et al., 2007). Morphine has been used for a long time as an effective treatment for pain (Zhang et al., 2008). Although many studies have shown that chronic exposure to morphine can impair long-

term potentiation, a form of plasticity that is considered as a possible basis for learning and memory in the brain and cause cognitive deficits (Spain and Newsom, 1991; Salmazadeh et al., 2003; Bao et al., 2007). There are studies that show Low doses of morphine, can enhance long-term memory recognition (Zarrindast et al., 2013). Also several lines of

evidence suggest that morphine may be neuroprotective. In rat neonatal hypoxia–ischemia model, morphine application after hypoxia decreases infarct volume in the brain (Zhou et al., 1998). In zebrafish embryos, morphine,emorphineances neuron proliferation(Sanchez-Simon et al., 2010).

In rat primary mesencephalic neuron morphine is found to be protective against 1-methyl-4-phenylpyridinium-induced dopaminergic neurotoxicity (Qian et al., 2007). In the CA1 regions of hippocampal slices morphine preconditioning reduced ischemia-induced celldeath (Zhao et al., 2006).In mouse hippocampal slices with oxygen-glucose deprivation, morphine preconditioning is reported to improve neuronal cell survival rate through protein kinase C ϵ (PKC ϵ)(Liu et al., 2008).In rat neuronal/glia cultures, morphine is reported to prevent cell death induced by HIV (Avdoshina et al., 2010).It has been shown that morphineandendormorphin can protect against intracellular amyloid β (iA β) toxicity in human and rat primary neuronal cultures and in rat brains in vivo.

Morphine reverses the electrophysiological changes induced by iA β . Morphine improves the spatial memory performance in rats infected by iA β packaged virus and in APP/PS1 mice in Morris water maze tests (Cui et al., 2011).Also in this study it has been shown that morphine protection is mediated through inducing estradiol release in hippocampal neurons, possibly by increasing P450 cytochrome aromatase activity. Released estradiol induces upregulation of heat shock protein 70 (Hsp70). Hsp70 protects against intracellular amyloid toxicity by rescuing proteasomal activity which is impaired by iA β (Cui et al., 2011).In the present study, the effects of morphine treatment upon impairment of spatial memory acquisition induced by icv injection of STZ have been investigated in rats.

MATERIALS AND METHODS

56 Adult male Wistar rats (Razi Institute, Karaj, Iran), weighing 200–300 g were used for Morris

Water Maze apparatus. Animals were kept in an animal house with a 12/12-h light–dark cycle and controlled temperature (22 ± 2 °C). Animals had free access to food and tap water except during the limited periods of experiments.

Eight animals were used in each group; each animal was used once only and killed immediately after the experiment. Behavioral experiments were done during the light phase of the light/dark cycle (light on 07:00). Animals were divided into 7 experimental groups: control, vehicle (Saline), STZ, STZ+ saline and STZ+ morphine groups. Rats in the saline andmorphine groups received saline (0.2ml) ormorphine(1, 2.5 and 5 mg/kg, i.p.) for 10 days one week after i.c.v, injection of STZ (Zarrindast et al., 2006).All drugs were prepared immediately prior to use and given intra peritoneally (i.p.) in a volume of 0.1 ml per 100 g body weight of rats. For induction of AD, STZ (3 mg/kg, i.c.v, 10 μ l each) was administered bilaterally into lateral ventricles. In the vehicle group saline (10 μ l) was administered bilaterally into lateral ventricles.

Learning and memory performance of the rats was evaluated in the MWM starting 24 h after the last (18th day) saline and morphineinjection. All experiments were executed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institute of Health Publication No. 80-23, revised 1996) and were approved by the Research and Ethics Committee of Qazvin University of Medical Sciences.Morphine waspurchased from TEMAD Company, (Tehran, Iran).and STZ was purchased from SIGMA-ALDRICH Company and anesthetic drugs (ketamine and xylazine) are products of Alfasan Company, Holland.Morphineand STZ,were dissolved in saline.

Induction of experimental dementia of AD by i.c.v. administration of STZ in rats

For induction of AD, Prior to surgery, rats were anesthetized with a combination of ketamine (100 mg/kg, ip) and xylazine (5 mg/kg, ip). The animal's head was fixed in the stereotaxic frame (stolting, USA).The scalp was cleaned with iodine

solution, and two holes were drilled in the skull bilaterally over the lateral ventricles. According to Paxinos and Watson's atlas (Paxinos 1997), the following coordinates were used for icv injection of STZ: 0.8 mm posterior to the bregma, 1.5 mm lateral to the sagittal suture, and 3.6 mm ventral from the surface of the brain with the tooth bar set at 0 mm. STZ was dissolved in normal saline shortly before use.

STZ (3 mg/kg, i.c.v 10 μ l each) were administered bilaterally (Monisha et al 2001, Sodhi et al 2013, Tiwari et al 2009, Jessié et al 2014). The same surgical procedures were also used in the vehicle (saline) group, (10 μ l/injection site). To determine that STZ was administered exactly into the cerebral ventricles, some rat (30%) were injected with 5 μ l of diluted potent blue dye and their brains were examined macroscopically after sectioning. After surgery, rats were housed individually, and three weeks later MWM test were performed to assess learning and memory.

Assessment of spatial learning and memory using the Morris water maze

To assess spatial learning and memory of animals, MWM tests were performed according to our previous work (Esmaeili et al 2016). Briefly, in MWM animal learns to escape to a hidden platform by swimming in circular water tank. This tank consisted of a large circular black colored pool of 150 cm diameter, 60 cm height, filled to a depth of 40 cm with water at 25 ± 1 °C. A black colored round platform of 10 cm diameter was placed 1 cm below the surface of water in a constant position in the middle of the target quadrant (Q2) in the pool; the starting point was in the Q1 quadrant in all the trials. The rats could climb on the platform to escape from the necessity of swimming.

Only distal visual cues were available. The task was divided into two sessions: place learning and probe test. The rats were given a maximum time of 60 s (cut-off time) to find the hidden platform and were allowed to stay on it for 20 s. Once the animal found it, it was allowed to remain there for 20 s. If it did not find the platform after 60s, it was

guided gently onto the platform and allowed to remain there for 20s.

The animals were given a daily session of 4 trials per day for 6 consecutive days. The numbers of quadrants crossed by the animals and path length (swimming paths) and latency time to reach the platform were recorded in each trial by water maze software. Twenty-four hours after the last acquisition session, a 'probe trial' was used to assess the spatial memory. During this trial, the platform was removed from the maze and the rat was allowed to search the pool for 60 s. The mean time spent by the animal in the target quadrant (Q2) searching for the hidden platform was measured and noted as an index of memory.

To assess whether any motivational factors interfered with the rat's ability to escape, 24h after probe test, a visible platform test was designed in which escape could be guided by proximal rather than distal spatial cues visible platform test (cue learning). During this trial, the platform was elevated above the water surface and extra maze cues were removed from the walls and the rats were allowed to swim freely for 60 s. The distance to platform (swim length), the escape latency and the number of quadrants crossed by the animals were measured. This test was aimed as measuring the visuo-motor abilities and the motivation of the animals.

STATISTICAL ANALYSES:

Data are expressed as mean \pm SEM (standard error of mean). In order to compare the latency time and path length to reach the platform (distance) and values for the probe trial in MWM were assessed by one-way ANOVA followed by Tukey's test to detect statistical differences between the groups. P values less than 0.05 were considered to be statistically significant.

RESULTS AND DISCUSSION

Place learning

Figures 1 and 2 display place learning of different experimental groups in the MWM. As expected, the average escape latency (The latency time to find the hidden platform), escape distance (the

path length to find the platform) in searching for the hidden platform decreased with the increase in training days. In the control and vehicle groups there were shorter average escape latency and distance (Fig. 1, 2). The percentages of total time elapsed and distance swum in the target quadrant in the probe test were also relatively higher but there was no significant difference between these two groups (Figs. 4).

An i.c.v. injection of 3mg/kg STZ, however, resulted in a significant decline in spatial learning, with longer latency and distance in searching for the underwater platform. These results indicate that STZ could significantly impair spatial learning and memory in rats. So the difference between control and STZ/STZ+ saline groups on all of training days were significant ($p < 0.05$). Our results also showed that treatment with low doses of morphine (1 and 2.5 mg/kg) protected spatial learning against impairment induced by STZ. As shown in Fig. 1- 2, treatment with low doses of morphine (1, 2.5 mg/kg) for 10 days, reversed the spatial learning and memory impairments induced by STZ.

Compared to the STZ/STZ+ saline groups, the average escape latency (Fig. 1B) and average escape distance (Fig. 2B) in searching for the hidden platform significantly decreased in the morphine (1, 2.5 mg/kg) plus STZ groups. Although the differences between the control with STZ/STZ+ saline groups on all of the training days were significant, such differences were not observed between the control and morphine (2.5 mg/kg) plus STZ group.

On the other hand treatment with high doses of morphine (5 mg/kg) led to further impairment of spatial learning and memory in the STZ rat model of sporadic AD. The escape latency and distance and the number of crossed quadrants in searching for the hidden platform in the STZ+ morphine (5

mg/kg) group rats similar to STZ/STZ+ saline groups were significantly higher than the control groups. Also, our results show that swimming speed of all groups of rats increased in the consecutive training days. But there were no significant difference between experimental groups indicating both STZ and morphine treatment had no effect on the motor activity of rats.

Probe test

In the probe test, control and vehicle group's rats spent most time and swum most in the target quadrant indicating memory consolidation were took place well in this group. However, in the STZ/STZ+ saline groups, (Fig. 4) time spent and swimming distance in the target quadrant were significantly less than those in control and vehicle groups. On the other hand, in the STZ + morphine treatment (1 and 2.5mg/kg) groups, time spent and swimming distance in the target quadrant were close to those in control group rats. The percentage of time spent and distance swimming in the target quadrant in the STZ plus morphine (2.5mg/kg) groups rats similar to control group rats were significantly higher than those in the other STZ-induced AD groups.

The percentage of total time elapsed and the distance swum in the target quadrant decreased in the morphine (5 mg/kg) plus STZ group, compared to the control group. Low doses of morphine (1 and 2.5mg/kg) increased time spent and swimming distance in the target quadrant in probe test whereas high doses of morphine has opposite effects.

Indicating that low doses of morphine treatment attenuated STZ- induced impairment in memory consolidation.

However, morphine treatment had no effect on the swimming speed.





Fig.1. Place learning. The upper panel shows the escape latency (the latency time to find the hidden platform) of the experimental groups during successive training days (four sessions per day). The lower panel shows the escape latency in all of the 6 training days. * $p < 0.05$; ** $p < 0.001$; relative to the control group, # $p < 0.05$, relative to the STZ group, one-way repeated measure of ANOVA followed by the Tukey Post Hoc Test.






Fig. 2.Place learning. The upper panel shows the distance (the path length to find the platform) of the experimental groups during successive training days. The lower panel shows the distance in all of the 6 training days. * $p < 0.05$; ** $p < 0.001$; relative to the control group, # $p < 0.05$, relative to the STZ group, one-way repeated measure of ANOVA followed by the Tukey Post Hoc Test.




Fig 3.Place learning. The panel shows the animals' swimming speed in the experimental groups during successive training days. There was no significant difference between experimental groups.




Fig. 4.Probe test. The panel shows the percentage of time spent in the target quadrant during only one day in the experimental groups. Each value represents the mean \pm SEM of the percentage of time spent in the target quadrant. * $p < 0.05$; ** $p < 0.001$; relative to the control group, one-way repeated measure of ANOVA followed by the Tukey Post Hoc Test.

DISCUSSION

The opioid system plays an important role in memory processes. Morphine mimics endogenous opioids by acting on opioid receptor in brain to regulate memory. However, the effects of morphine on spatial memory acquisition are controversial. Low doses of morphine, comparable with endogenous brain concentrations, enhanced long-term memory recognition; while high doses did the reverse. In this regard Zarrindast et al., 2013 have showed that social memory formation appears to be impaired in presence of morphine at analgesic doses (mg kg⁻¹). In contrast, opposite effect was induced on memory formation by morphine at low (μ g kg⁻¹) doses. Several studies have reported facilitation of memory retention by opioid antagonists such as naloxone, whereas the systemic administration of morphine at analgesic doses impairs memory processes (Izquierdo, 1980). In the present study, we investigated the effects of morphine treatment on impairment of spatial memory acquisition induced by i.c.v injection of STZ (3 mg/kg, 10 μ l/injection site) in adult male rats. The results indicated that bilateral pre-training, i.c.v injection of STZ impaired acquisition of spatial memory on the training and test day. The amnesic effect of STZ was decreased in rats treated daily with morphine (1 and 2.5 mg/kg, ip) for 10 days. The results suggest that sub-chronic morphine treatment at low doses may have protective effect against STZ-induced neurotoxicity which in turn reversed the impairment of spatial learning and memory acquisition induced by STZ. In agreement with our result several lines of evidence suggest that morphine may have neuroprotective effects against damage in the neuronal system. For example (Zarrindast et al., 2011) have shown that morphine administration for 3 day could attenuate deficits in memory consolidation produced by post training intra dorsal hippocampus (intra-CA1) administration of the non-selective cannabinoid CB1/CB2 receptor agonist, WIN55, 212-2. Likewise Farahmandfar et al 2013 have shown that bilateral pre-training

intra-CA1 infusions of WIN55,212 impaired acquisition of spatial memory and this amnesic effect of WIN55, 212-2 was prevented with morphine. Also it has been shown that chronic pretreatment with morphine could decrease memory impairment by peripheral (Zarrindast and Rezayof, 2004) and central (ventral tegmental area) (Zarrindast et al., 2005a) administrations of morphine or histamine (Zarrindast et al., 2006c). Morphine treatment can enhance conditioned place preference when injected in the ventral pallidum (Roohbakhsh et al., 2007). Several reports have addressed the neuroprotective effect of morphine against damage in the neuronal system. In this regard it has been shown that morphine, endomorphin-1 and endomorphin-2 can protect against iA β toxicity in human and rat primary neuronal cultures and in rat brains in vivo. Furthermore Morphine can improve the spatial memory performance in rats infected by iA β packaged virus. Also it has been shown that Morphine protection is mediated through inducing estradiol release in hippocampal neurons, possibly by increasing P450 cytochrome aromatase activity. Released estradiol induces up regulation of heat shock protein 70 (Hsp70). Hsp70 protects against intracellular amyloid toxicity by rescuing proteasomal activity which is impaired by iA β (Cui et al., 2011). Our results suggest that Low doses of Morphine (1 and 2.5 mg/kg), facilitates, whereas higher doses of Morphine (5 mg/kg), impairs, learning and memory in STZ-induced rat model of sporadic AD. Morphine is indicated to modify cell death/survival and play anti apoptotic roles in neurons of the CNS. However, the mechanisms of morphine protection are not clear yet. In this regard previous studies have shown that Activation of PKC epsilon isoform is important in mediating the Preconditioning protection against necrosis and apoptosis induced by ischemia. Morphine pretreatment dose-dependently increased neuronal cell survival after oxygen and glucose deprivation. It has been shown that morphine preconditioning-induced ischemia

tolerance is mediated through novel PKC ϵ (nPKC ϵ) isoform and NMDA receptors because morphine protection is greatly reduced by ev1–2 and MK-801 as nPKC ϵ and NMDA receptor-specific antagonists or by blockage of membrane translocations of nPKC ϵ and NMDA receptors (Liu et al., 2001; Fanjun et al., 2006). It has been shown that the extent of PKCs translocation to the cell membrane during ischemia correlates well with the extent of cell injury. It has been shown that morphine pretreatment inhibited nPKC ϵ membrane translocation during the period of reperfusion, in mouse hippocampal slices and administration of ev1–2 stopped the inhibition of nPKC ϵ translocation, which suggested that nPKC ϵ might be involved in the neuroprotection of morphine (Fanjun et al., 2006). The results suggested that moderate activation of NMDA receptors or nPKC ϵ might be involved in morphine pretreatment-induced neuroprotection although other study has suggested that neuroprotection effect of morphine is mediated via nitrogen oxide release.

It is proposed that morphine-induced nitrogen oxide release mediates neuroprotection in a human neuroblastoma cell line against intracellular oxidative stress and neuroinflammation and extracellular A β toxicity (Rambhia et al., 2005). In this regard, other mechanisms have been suggested, including: Protection of morphine against peroxynitrite induced apoptosis in primary rat neonatal astrocytes is mediated by phosphoinositide 3-kinase (Kim et al., 2001). Downregulation of BACE-1 (beta-site amyloid precursor protein cleaving enzyme 1) and upregulation of BACE-2 has been shown to decrease beta-amyloid peptide levels. It has been shown that Morphine can down regulate the expression of BACE-1 and up regulates the expression of BACE-2 in human neuroblastoma HTB-11 cells. Because in this study when HTB-11 cells were treated with NO synthase inhibitor (L-NAME), the neuroprotection effects of morphine were blocked. (Pak et al., 2005). Based on the above evidences and our data, we thought

that the changes in the nitrogen oxide release and in the activity of nPKC ϵ and NMDA receptors might be involved in the neuroprotection induced by morphine treatment. On the other hand our result show that higher doses of Morphine (5 mg/kg), impairs, learning and memory in STZ-induced rat model of sporadic AD. Memory is often considered to be a process that has several stages including acquisition, consolidation, and retrieval. In this regard many reports have demonstrated that pre- or post-training administrations of moderate doses of morphine (5 – 10 mg/kg) impairs learning and memory of behavioral tasks (Izquierdo, 1979, 1980, Bruins Slot, 1999, Ahmadi, 2007 Jafari, 2006 Rezayof 2006 Zarrindast, 2013). Several studies have reported facilitation of memory retention by opioid antagonists such as naloxone, whereas the systemic administration of morphine at analgesic doses impairs memory processes (Izquierdo, 1980). There is some evidence that shown chronic exposure to morphine can impair long-term potentiation (LTP), and cause cognitive deficits (Bliss and Collingridge, 1993) (Spain and Newsom, 1991), it has been shown that chronic exposure to morphine leads to the impairment of hippocampal CA1 LTP (Pu et al., 2002; Salmanzadeh et al., 2003; Bao et al., 2007) and induces cognitive deficits (Pu et al., 2002; Miladi Gorji et al., 2008). Accumulating evidence has demonstrated that chronic exposure to morphine diminishes hippocampal CA1 LTP (Pu et al., 2002; Salmanzadeh et al., 2003) and leads to the impairment of acquisition (Spain and Newsom, 1991; Li et al., 2001) or retention (Alaei et al., 2006; Miladi Gorji et al., 2008) of spatial memory via accumulation of extracellular adenosine (Gang. et al., 2010). In conclusion, these results demonstrated that Low doses of Morphine (1 and 2.5 mg/kg), facilitates, whereas higher doses of Morphine (5 mg/kg), impairs, learning and memory in STZ-induced rat model of sporadic AD. It seems that morphine's route of administration and the doses used are critical elements defining the morphine effect on learning

and memory. Morphine treatment administration may either disrupt or facilitate spatial memory, in STZ-induced rat model of sporadic AD, depending on the dose, The bimodal effects of morphine previously shown in Social memory and pain.(Bianchi, 2013;Jacquet and Lajtha, 1973;Kayser et al., 1987 ; Crain and Shen, 2001) Biphasic dose–response relationships have been demonstrated in animals following administration of morphine (Jacquet and Lajtha, 1973). Beyond the analgesic effect exerted by morphine at analgesic doses, acute thermal hyperalgesia has been demonstrated by different researchers after morphine administration to animals at extremely low doses (Kayser et al., 1987; Crain and Shen, 2001).

REFERENCES:

1. Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. *Annu Rev Neurosci* 21:479–505.
2. Li M, Chen L, Lee DH, Yu LC, Zhang Y (2007). The role of intracellular amyloid beta in Alzheimer's disease. *Prog Neurobiol* 83:131–139.
3. Zhang Y, Chen Q, Yu LC (2008)Morphine: a protective or destructive role in neurons? *Neuroscientist* 14:561–570.
4. Salmazadeh F, Fathollahi Y, Semnani S, Shafizadeh M. Dependence on morphine impairs the induction of long-term potentiation in the CA1 region of rat hippocampal slices. *Brain Res.* 2003; 965(1-2):108-13.
5. Bao G1, Kang L, Li H, Li Y, Pu L, Xia P, Ma L, Pei G. Morphine and heroin differentially modulate in vivo hippocampal LTP in opiate-dependent rat. *Neuropsychopharmacology.* 2007 Aug; 32(8):1738-49.
6. Spain JW1, Newsom GC. Chronic opioids impair acquisition of both radial maze and Y-maze choice escape. *Psychopharmacology (Berl).* 1991;105 (1):101-6.
7. Zhou Q, Krebs JF, Snipas SJ, Price A, Alnemri ES, Tomaselli KJ, Salvesen GS (1998) Interaction of the baculovirus anti-apoptotic protein p35 with caspase-specificity, kinetics, and characterization of the caspase/p35 complex. *Biochemistry* 37:10757–10765.
8. Sanchez-Simon FM, Arenzana FJ, Rodriguez RE (2010)*In vivo* effects of morphine on neuronal fate and opioid receptor expression in zebrafish embryos. *Eur J Neurosci* 32:550–559.
10. Qian L, Tan KS, Wei SJ, Wu HM, Xu Z, Wilson B, Lu RB, Hong JS, Flood PM.(2007) Microglia-mediated neurotoxicity is imorphineibited by morphine through an opioid receptor-independent reduction of NADPH oxidaseactivity. *J Immunol* 179:1198–1209.
11. Zhao P, Huang Y, Zuo Z (2006) Opioid preconditioning induces opioid receptor-dependent delayed neuroprotection against ischemia in rats.
12. *J NeuropatholExpNeurol* 65:945–952.
13. Liu Y, Nie YM, Wu WK (2008) [The effect of PKC activation and Smac release on imorphineibition of myocardial cell apoptosis by Sini Decoction].*Zhong Yao Cai* 31:1675–1678.
14. Avdoshina V, Biggio F, Palchik G, Campbell LA, Mocchetti I (2010) Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. *Glia* 58:1630–1639.
15. Jia Cui, Yunfeng Wang, Qiping Dong, Shimin Wu, Xianzhong Xiao, Jianying Hu, Zhen Chai, and Yan Zhang. Morphine Protects against Intracellular Amyloid Toxicity by Inducing Estradiol Release and Upregulation of Hsp70. *The Journal of Neuroscience,* November 9, 2011 31(45):16227–16240
16. Zarrindast MR, Ebrahimi M, Khalilzadeh A (2006). Influence of ATP-sensitive potassium channels on lithium state-dependent memory of passive avoidance in mice. *European Journal of Pharmacology* 550 107–111.
17. Paxinos G and Watson C (1997).The rat brain in stereotaxic coordinates, *3rd edn, Academic Press, San Diego.*

18. Monisha Sharma, Y and Gupta K (2001). Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. *Life Sciences* 68 1021–1029.
19. Sodhi RK and Singh N (2013). All-trans retinoic acid rescues memory deficits and neuropathological changes in mouse model of streptozotocin-induced dementia of Alzheimer's type. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 40 38–46.
20. Tiwari V, Kuhad A, Bishnoi M and Chopra K (2009). Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative–nitrosative stress in rats. *Pharmacology Biochemistry Behavior* 93 183–189.
21. Jessié M. Gutierrez, Fabiano B. Carvalho, Maria Rosa C. Schetinger, Patrícia Marisco and Paula Agostini (2014). Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer's type. *Life Sciences* 96 7–17.
22. Esmaeili MH, Mafe Esmaeili M (2016). Metformin improves learning and memory in streptozotocin-induced rat model of sporadic Alzheimer's disease. *Indian Journal of Fundamental and Applied Life Sciences* 6 270–281.
23. Izquierdo, Dias RD, Souza DO, Carrasco MA, Elisabetsky E, Perry ML. The role of opioid peptides in memory and learning. *Behav Brain Res.* 1980;1(6):451–68.
24. Roohbakhsh, A., Moghaddam, A.H., Massoudi, R., Zarrindast, M.R., 2007. Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety-like behaviours in rats using the elevated plus-maze test. *Clin. Exp. Pharmacol. Physiol.* 34, 223–229.
25. Zarrindast MR, Ardjmand A, Rezayof A, Ahmadi S. The time profile of morphine effect on different phases of morphine inhibitory avoidance memory in rat. *Arch Iran Med.* 2013; 16(1):34–7.
26. Zarrindast MR1, Navaeian M, Nasehi M. Influence of three-day morphine-treatment upon impairment of memory consolidation induced by cannabinoid infused into the dorsal hippocampus in rats. *Neurosci Res.* 2011 Jan;69(1):51–9.
27. Zarrindast, M.R., Farajzadeh, Z., Rostami, P., Rezayof, A., Nourjah, P., 2005a. Involvement of the ventral tegmental area (VTA) in morphine-induced memory retention in morphine-sensitized rats. *Behav. Brain Res.* 163, 100–106.
28. Zarrindast, M.R., Khalilzadeh, A., Malekmohammadi, N., Fazli-Tabaei, S., 2006c. Influence of morphine- or apomorphine-induced sensitization on histamine state-dependent learning in the step-down passive avoidance test. *Behav. Brain Res.* 171, 50–55.
29. Zarrindast, M.R., Rezayof, A., 2004. Morphine state-dependent learning: sensitization and interactions with dopamine receptors. *Eur. J. Pharmacol.* 497, 197–204.
30. Farahmandfar M, Kadivar M, Naghdi N, Chooapani S, Zarrindast MR. Influence of pre-exposure to morphine on cannabinoid-induced impairment of spatial memory in male rats. *Behav Brain Res.* 2013; 256:157–64.
31. Farahmandfar, M., Karimian, S.M., Naghdi, N., Zarrindast, M.R., Kadivar, M., 2010. Morphine-induced impairment of spatial memory acquisition reversed by morphine sensitization in rats. *Behav. Brain Res.* 211, 156–163.
32. Fanjun M, Junfa L, Bingxi Z, Fang J (2006). nPKCε and NMDA receptors participate in neuroprotection induced by morphine pretreatment. *J Neurosurg Anesthesiol* 18:119–124.
33. Liu H, McPherson BC, Yao Z (2001). Preconditioning attenuates apoptosis and necrosis: role of protein kinase C ε and -δ isoforms. *Am J Physiol Heart Circ Physiol* 281:H404–410.

34. Rambhia S, Mantione KJ, Stefano GB, Cadet P (2005) Morphine modulation of the ubiquitin-proteasome complex is neuroprotective. *Med Sci Monit* 11:BR386–BR396.
35. Kim MS, Cheong YP, So HS, Lee KM, Kim TY, Oh J, Chung YT, Son Y, Kim BR, Park R (2001) Protective effects of morphine in peroxynitrite-induced apoptosis of primary rat neonatal astrocytes: potential involvement of G protein and phosphatidylinositol 3-kinase (PI3 kinase).
36. *Biochem Pharmacol* 61:779–786.
37. Pak T, Cadet P, Mantione KJ, Stefano GB (2005) Morphine via nitric oxide modulates beta-amyloid metabolism: a novel protective mechanism for Alzheimer's disease. *Med Sci Monit* 11:BR357–BR366.
38. Gang Lu^{1,*}, Qi-Xin Zhou^{2,*}, Shuo Kang¹, Qing-Lin Li³, Liang-Cai Zhao³, Jia-Dong Chen⁴, Jian-Feng Sun¹, Jun Cao², Yu-Jun Wang¹, Jie Chen¹, Xiao-Yan Chen¹, Da-Fang Zhong¹, Zhi-Qiang Chi¹, Lin Xu², Jing-Gen Liu¹. Chronic Morphine Treatment Impaired Hippocampal Long-Term Potentiation and Spatial Memory via Accumulation of Extracellular Adenosine Acting on Adenosine A1 Receptors. *The Journal of Neuroscience*, 7 April 2010, 30(14): 5058-5070; doi: 10.1523/JNEUROSCI.0148-10.2010
39. Izquierdo I. Effect of naloxone and morphine on various forms of memory in the rat: possible role of endogenous opiate mechanisms in memory consolidation. *Psychopharmacology (Berl)*. 1979; 66: 199–203.
40. Izquierdo I. Effect of beta-endorphin and naloxone on acquisition, memory, and retrieval of shuttle avoidance and habituation learning in rats. *Psychopharmacology (Berl)*. 1980; 69: 111–115.
41. Bruins Slot LA, Colpaert FC. Opiate states of memory: receptor mechanisms. *J Neurosci*. 1999; 19: 10520–10529.
42. Ahmadi S, Zarrindast MR, Haeri-Rohani A, Rezayof A, Nouri M. Nicotine improves morphine-induced impairment of memory: possible involvement of N-methyl-D-aspartate receptors in the nucleus accumbens. *Dev Neurobiol*. 2007; 67: 1118–1127.
43. Jafari MR, Zarrindast MR, Djahanguiri B. Influence of cholinergic system modulators on morphine state-dependent memory of passive avoidance in mice. *Physiol Behav*. 2006; 88: 146–151.
44. Rezayof A, Amini R, Rassouli Y, Zarrindast MR. Influence of nitric oxide on morphine-induced amnesia and interactions with dopaminergic receptor agents. *Physiol Behav*. 2006; 88: 124–131.
45. Mohammad Reza Zarrindast, Abolfazl Ardjmand, Ameneh Rezayof, Shamseddin Ahmadi The Time Profile of Morphine Effect on Different Phases of Inhibitory Avoidance Memory in Rat. *Archives of Iranian Medicine*, Volume 16, Number 1, January 2013
46. Bianchi E, Menicacci C, Ghelardini C. Dual effect of morphine in long-term social memory in rat. *Br J Pharmacol*. 2013 Apr; 168(8):1786–93.
47. Kayser V, Besson JM, Guilbaud G (1987). Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats). *Brain Res* 414: 155–157.
48. Crain SM, Shen KF (2001). Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. *Brain Res* 888:75–82.
49. Jacquet YF, Lajtha A (1973). Morphine action at central nervous system sites in rat: analgesia or hyperalgesia depending on site and dose. *Science* 182: 490–492.